news
Compass Files First Psilocybin Treatment Application With FDA
Compass Pathways submitted a New Drug Application to the FDA for COMP360, its proprietary psilocybin formulation for treatment-resistant depression. The treatment pairs a single 25mg dose with psychological support from trained monitors. If approved, it will be the first legal psychedelic-assisted medicine authorized by federal regulators.
Compass Pathways submitted a New Drug Application to the FDA for COMP360, its proprietary psilocybin formulation for treatment-resistant depression. The treatment pairs a single 25mg dose with psychological support from trained monitors. If approved, it will be the first legal psychedelic-assisted medicine authorized by federal regulators.
The architecture take
After the FDA rejected Lykos's MDMA application last summer, everyone in psychiatry held their breath to see who'd step onto the ice next. Compass just did. COMP360 targets 5-HT2A serotonin receptors to quiet the default mode network, giving stubborn depressive thought loops a temporary reboot. The clinical pitch is tidy: one 25mg dose under supervision with trained therapists, aiming to bump neuroplasticity for months. But the real hurdle here hasn't been whether psilocybin changes brain states. That's clear. The fight is over the delivery model. Regulators hated Lykos's messy psychotherapy data, and Compass is gambling that a standardized protocol will satisfy an agency that gets nervous around altered states. I suspect the FDA will slap this with strict safety mandates. You won't be picking this up at a local CVS anytime soon. Expect mandatory six-hour clinic visits, certified monitors, and hefty price tags that insurers will fight before paying.